CD8A and liver cancer: SCFAs have been shown to downregulate the expression of PD-1 in CD8+ T cells within the liver cancer microenvironment, thereby mitigating T cell exhaustion and enhancing the efficacy of anti-PD-1/PD-L1 immunotherapy.